Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base
Open Access
- 6 April 2015
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 7 (4), 198-205
- https://doi.org/10.1177/1758834015579313
Abstract
Pancreatic cancer accounts for approximately 7% of all cancer deaths. More than half of all pancreatic cancers are stage IV at diagnosis, where systemic chemotherapy is used with the goal of life prolongation as well as palliation. The patient characteristics and health system factors that drive the use of systemic therapy are unknown. This is a retrospective study of stage IV pancreatic cancer patients (n = 140,210) diagnosed between 2000 and 2011 in the NCDB. NCDB contains approximately 70% of new cancer diagnosis from more than 1500 accredited cancer programs in the United States and Puerto Rico. Chi-squared test was used to determine any differences in characteristics of patients who did or did not receive systemic therapy. Our study demonstrated that only 49.1% of stage IV pancreatic cancer patients received systemic therapy. The use of systemic therapy is significantly lower in female, African American/Hispanic, patients older than 40 years, those without insurance or with Medicare and Medicaid, higher Charlson Comorbidity Score, poor economic and educational status and in nonacademic centers. This is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in patients older than 40 years, lower educational status, nonprivate insurance and with higher Charlson Comorbidity Scores. In addition, the use of systemic therapy was lower with female sex, African Americans/Hispanic, and lower socio-economic status. Understanding the barriers in the use of systemic therapy as well as appropriate utilization of systemic therapy can both optimize cancer care.This publication has 36 references indexed in Scilit:
- Assessment of Advanced Gastric Cancer Management in the United StatesAnnals of Surgical Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Systemic Therapy for Elderly Patients with Gastrointestinal CancerClinical Medicine Insights: Oncology, 2011
- Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcomeEuropean Journal of Cancer, 2010
- Pain and Emotional Well-Being Outcomes in Southwest Oncology Group–Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas CancerJournal of Clinical Oncology, 2010
- Education and Risk of Cancer in a Large Cohort of Men and Women in the United StatesPLOS ONE, 2008
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 2008
- National Failure to Operate on Early Stage Pancreatic CancerAnnals of Surgery, 2007
- Do Oncologists Believe New Cancer Drugs Offer Good Value?The Oncologist, 2006
- The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: palliative chemotherapy and watchful-waitingEuropean Journal of Cancer, 2004